No Data
No Data
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Addition to the Russell 2000 Index
Providence, RI, May 25, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ:OCEA) announced today that it is expected to be added to the Russell 2000 Index, effective after the U.S. market opens on June 26, 2023.
Ocean Biomedical, Inc. Enters Into a $25 Million Convertible Note Facility
Providence, RI, May 16, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development and commercialization of scientifically compelling a
Ocean Biomedical (NASDAQ: OCEA) Announces Notice of Allowance for U.S. Patent Application for Breakthrough Pulmonary Fibrosis Treatments Issued to Scientific Co-founder Dr. Jack A. Elias.
Providence, RI, April 20, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development and commercialization of scientifically compelling
Ocean Biomedical (NASDAQ: OCEA) Will Target Pulmonary Fibrosis Discoveries as Novel Treatments of Hermansky-Pudlak Syndrome
On Hermansky-Pudlak Syndrome (HPS) Awareness Day, Ocean Biomedical announces a commitment to developing viable treatment options for HPS-1 and HPS-4 Providence, RI, April 06, 2023 (GLOBE NEWSWIRE) -
Ocean Biomedical (NASDAQ: OCEA) Announces Initiation of Equity Analyst Coverage by Fundamental Research Corp. With a "Buy" Recommendation
Providence, RI, March 16, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a next generation biopharma company, announces initiation of equity analyst coverage by Fundamental Research
Ocean Biomedical (NASDAQ: OCEA) Announces Initiation of Equity Analyst Coverage by EF Hutton With a "Buy" Recommendation
Providence, RI, March 14, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ:OCEA), a next generation biopharma company, announces initiation of equity analyst coverage by EF Hutton with a "Buy" recommendation.
No Data